Adicet Bio, Inc. (0HX7.L)

USD 0.92

(-3.81%)

Market Cap (In USD)

76.17 Million

Revenue (In USD)

-

Net Income (In USD)

-142.65 Million

Avg. Volume

6355.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.9245-7.6
PE
-
EPS
-
Beta Value
1.698
ISIN
US0070021086
CUSIP
76133L103
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Employee Count
-
Website
https://www.adicetbio.com
Ipo Date
2021-01-08
Details
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.